# Neoadjuvant chemotherapy with bevacizumab for locally advanced vulvar cancer.

**Tumor:** Ginecológico
**Autores:** Kuhn TM
**Revista:** Int J Gynecol Cancer (2024)
**PMID:** 38830645 | **PMCID:** —
**DOI:** [10.1136/ijgc-2024-005402](https://doi.org/10.1136/ijgc-2024-005402)
**Fuente:** PubMed (abstract only)

## Relevancia
Cáncer ginecológico (cervix, vulva) tratado con quimioterapia neoadyuvante: pCR ganglionar pélvico/inguinal, downstaging y selección para cirugía preservadora de fertilidad o vulvectomía. Aporta paralelos con mama en la cirugía de menor extensión tras buena respuesta nodal a NAC.

## Abstract
We describe clinical outcomes for patients who received neoadjuvant chemotherapy plus bevacizumab followed by radical vulvectomy for locally advanced vulvar cancer. 13 patients underwent neoadjuvant chemotherapy. Nine (69.2%) had partial pathologic responses, and four had complete responses. All patients had negative surgical margins. Ten (76.9%) had radiographic evidence of inguinal lymph node metastasis prior to neoadjuvant chemotherapy, and four had residual nodal disease. Three patients developed recurrence; one death. Neoadjuvant chemotherapy using combination platinum/paclitaxel/bevacizumab was efficacious for locally advanced vulvar cancer.

## Acceso
Vía [DOI](https://doi.org/10.1136/ijgc-2024-005402) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1136/ijgc-2024-005402*
